StockData
UroGen Pharma Ltd. logo

UroGen Pharma Ltd. (URGN) stock

URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$29.79−0.08 (-0.27%)

Close on Nov 18, 2026Market cap $1.46BP/E –Yield –

UroGen Pharma cash

Cash and short-term investments held at the end of each period.

UroGen Pharma's cash was $108.00M at Jun 30, 2026. For fiscal 2025 it was $120.50M, down 50.1% from the year before. Over ten years it grew 21.0% a year on average. The highest annual figure on record is $241.70M in fiscal 2024.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$120.50M-50.1%
FY2024Dec 31, 2024$241.70M+70.8%
FY2023Dec 31, 2023$141.50M+41.6%
FY2022Dec 31, 2022$99.96M+49.5%
FY2021Dec 31, 2021$66.88M-34.4%
FY2020Dec 31, 2020$102.02M-30.6%
FY2019Dec 31, 2019$147.08M+45.2%
FY2018Dec 31, 2018$101.32M+38.8%
FY2017Dec 31, 2017$73.00M+241.7%
FY2016Dec 31, 2016$21.36M+18.8%
FY2015Dec 31, 2015$17.98M+364.5%
FY2014Dec 31, 2014$3.87M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$108.00M-33.2%
Q1 FY2026Mar 31, 2026$140.30M-30.0%
Q4 FY2025Dec 31, 2025$120.50M-50.1%
Q3 FY2025Sep 30, 2025$127.40M-49.9%
Q2 FY2025Jun 30, 2025$161.60M-33.0%
Q1 FY2025Mar 31, 2025$200.40M+21.8%
Q4 FY2024Dec 31, 2024$241.70M+70.8%
Q3 FY2024Sep 30, 2024$254.20M+65.2%
Q2 FY2024Jun 30, 2024$241.30M+336.3%
Q1 FY2024Mar 31, 2024$164.50M+118.8%
Q4 FY2023Dec 31, 2023$141.50M+41.6%
Q3 FY2023Sep 30, 2023$153.90M+60.5%
Q2 FY2023Jun 30, 2023$55.30M-50.8%
Q1 FY2023Mar 31, 2023$75.20M-45.1%
Q4 FY2022Dec 31, 2022$99.96M+49.5%
Q3 FY2022Sep 30, 2022$95.90M-13.1%
Q2 FY2022Jun 30, 2022$112.40M-7.1%
Q1 FY2022Mar 31, 2022$137.10M+80.6%
Q4 FY2021Dec 31, 2021$66.88M-34.4%
Q3 FY2021Sep 30, 2021$110.30M-7.8%
Q2 FY2021Jun 30, 2021$121.03M-3.3%
Q1 FY2021Mar 31, 2021$75.91M-36.3%
Q4 FY2020Dec 31, 2020$102.02M-30.6%
Q3 FY2020Sep 30, 2020$119.62M-24.4%
Q2 FY2020Jun 30, 2020$125.12M-33.9%
Q1 FY2020Mar 31, 2020$119.09M-51.7%
Q4 FY2019Dec 31, 2019$147.08M+45.2%
Q3 FY2019Sep 30, 2019$158.19M+44.5%
Q2 FY2019Jun 30, 2019$189.16M+58.8%
Q1 FY2019Mar 31, 2019$246.69M+93.5%
Q4 FY2018Dec 31, 2018$101.32M+38.8%
Q3 FY2018Sep 30, 2018$109.48M+38.3%
Q2 FY2018Jun 30, 2018$119.11M+54.5%
Q1 FY2018Mar 31, 2018$127.46M+591.7%
Q4 FY2017Dec 31, 2017$73.00M+241.7%
Q3 FY2017Sep 30, 2017$79.17M+340.5%
Q2 FY2017Jun 30, 2017$77.09M–
Q1 FY2017Mar 31, 2017$18.43M–
Q4 FY2016Dec 31, 2016$21.36M–
Q4 FY2015Dec 31, 2015$17.98M–

More UroGen Pharma figures

See a number that looks wrong?